Loading
CRISPR Therapeutics AG Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 27 Jan 2026.
CRISPR Therapeutics AG: what insiders have been doing
CRISPR Therapeutics AG, founded in 2013, is a Healthcare & Pharma company based in Zug, Switzerland. Its directors and officers file their transactions with SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for CRISPR Therapeutics AG logged 39 filings by 9 insiders.
The record shows 1 purchase on the open market worth €45k, made by 1 insider, against 9 sales worth €3.5M by 6 insiders. The net balance comes to €3.5M on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. At €950k, the sale published on 22 January 2026 by Kulkarni Samarth is the largest of the period. On the buying side, the filings list 1 senior executive among the declarants.
The latest purchase dates back some time: it was published 264 days ago, on 27 January 2026. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Compared with its exchange (5,816 companies, median 19 filings), a count of 39 filings is above the norm. Looking back to 2021, when coverage begins, insiders filed 4 purchases and 19 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 3.5 m USD and net income at -581.6 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
126
Thresholds
n/a
Buy Volume
€2M
4 ops. · all time
Sell Volume
€15M
19 ops. · all time
Who traded when
BuySaleSamarth Kulkarni5 sales
James R. Kasinger3 sales
Naimish Patel1 buy2 sales
Simeon George1 buy1 sale
Ali Behbahani1 sale
Greene John1 buy
+2 other insiders
Since the insiders bought
- -3.0%Entry US$53.69 · Close at T+90 US$52.06
- -3.4%Entry US$55.41 · Close at T+365 US$53.51
- -27.9%Entry US$65.13 · Close at T+365 US$46.99
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate CRISPR Therapeutics AG Buy (bullish), based on 19 analysts. Average price target: US$85.63.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$51.52
Analyst consensus
19 analystsBuy
US$44.00Target US$85.63(+66%)US$291.00
Income statement
RevenueUS$3M
Gross profit-US$213.5M-7064% margin
EBITDA-US$645.1M-21346% margin
Net income-US$581.6M0.0% margin
Valuation
PER (forward)-14.5x
P/Book2.9x
Beta1.76
Balance sheet & cash
Market capUS$5B
Total debtUS$206.7M
Free Cash Flow-US$370.9M
Debt / Equity45%
Profitability & ownership
ROE-26.1%
ROA-14.2%
% insiders5.9%
% institutions78.2%
Last declaration on 16 October 2026
Declarations126 total
30,000 shares@ US$14.00Common SharesSEC:0001193125-26-424317:0
14,514 shares@ US$49.633Common SharesSEC:0001193125-26-424317:1
2,113 sharesCommon SharesSEC:0001193125-26-423057:0
1,040 shares@ US$49.260.0010% mcap4.9% of flowCommon SharesSEC:0001193125-26-423057:1
8,333 sharesCommon SharesSEC:0001193125-26-423056:0
4,098 shares@ US$49.260.0041% mcap1.5% of flowCommon SharesSEC:0001193125-26-423056:1
14,514 shares@ US$49.6330.014% mcap100.0% of flowCommonSEC144:0001950047-26-010218
1,990 shares@ US$13.620.0005% mcap2.7% of flowCommon SharesSEC:0001193125-26-418101:0
1,990 shares@ US$60.04080.0024% mcap12.0% of flowCommon SharesSEC:0001193125-26-418101:1
1,990 shares@ US$60.04080.0022% mcap16.3% of flowCommonSEC144:0001950047-26-010087
10,400 shares@ US$60.23650.012% mcap72.1% of flowCommon SharesSEC:0001193125-26-401237:1
10,400 shares@ US$13.620.0026% mcap16.3% of flowCommon SharesSEC:0001193125-26-401237:0
10,400 shares@ US$60.23650.012% mcap100.0% of flowCommonSEC144:0001950047-26-009755
30,000 shares@ US$14.000.0077% mcap35.0% of flowCommon SharesSEC:0001193125-26-396944:0
13,679 shares@ US$57.09010.014% mcap65.0% of flowCommon SharesSEC:0001193125-26-396944:1
60 shares0Common SharesSEC:0001193125-26-396935:0
15 shares0Common SharesSEC:0001193125-26-396935:1
13,679 shares@ US$57.09010.014% mcap100.0% of flowCommonSEC144:0001950047-26-009604
750 shares0Common SharesSEC:0001193125-26-345111:0
3,786 shares@ US$55.620.0039% mcap51.7% of flowCommon SharesSEC:0001193125-26-251817:1
10,000 sharesCommon SharesSEC:0001193125-26-251817:0
6,250 sharesCommon SharesSEC:0001193125-26-122274:0
19,687 sharesCommon SharesSEC:0001193125-26-122272:0
6,250 sharesCommon SharesSEC:0001193125-26-122268:0
8,125 sharesCommon SharesSEC:0001193125-26-111286:0
25 of 126 declarations
About CRISPR Therapeutics AG
CRISPR Therapeutics AG is a leading biotechnology company focused on genome editing and the development of transformative medicines for serious diseases. The company is listed on the U.S. Nasdaq market (United States) under the ticker CRSP, placing it among the most visible pure-play CRISPR names in the public markets. It was incorporated on October 31, 2013 in Switzerland, originally as Inception Genomics AG, and renamed CRISPR Therapeutics AG in 2014. Its corporate headquarters are in Zug, Switzerland, while research and development activities are anchored in the United States, particularly in Boston and San Francisco. ([crisprtx.gcs-web.com](https://crisprtx.gcs-web.com/investor-faqs?utm_source=openai))
The company’s flagship commercial asset is CASGEVY® (exagamglogene autotemcel, or exa-cel), the world’s first approved CRISPR-based therapy. Developed with Vertex, CASGEVY is a non-viral ex vivo gene-edited cell therapy for patients with severe sickle cell disease and transfusion-dependent beta thalassemia. Under the amended collaboration, Vertex leads global development, manufacturing, and commercialization, with profits and costs shared 60/40 worldwide. CASGEVY is now approved in multiple major markets, including the United States, the European Union, and Great Britain, making it the company’s key near-term commercial and strategic catalyst. ([crisprtx.gcs-web.com](https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr-therapeutics-highlights-strategic-priorities-and-0/?utm_source=openai))
Read moreShow less
Beyond CASGEVY, CRISPR Therapeutics is building a broader pipeline spanning in vivo liver editing, autoimmune disease, oncology, regenerative medicine, and cardiometabolic indications. Its LNP-based in vivo franchise includes CTX310, an ANGPTL3 program that moved into Phase 1b for severe hypertriglyceridemia and refractory hypercholesterolemia after encouraging Phase 1 data; CTX320 and the next-generation CTX321 for LPA; CTX460 for alpha-1 antitrypsin deficiency; and CTX340 for refractory hypertension. The company is also advancing zugo-cel, an allogeneic CAR-T candidate in autoimmune disease and hematologic malignancies, alongside a regenerative medicine program for type 1 diabetes and a siRNA collaboration with Sirius Therapeutics. ([ir.crisprtx.com](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-highlights-strategic-priorities-and-0))
From an equity-investment perspective, CRISPR Therapeutics has an important first-mover advantage in CRISPR medicine, supported by the historical approval of CASGEVY and a scientifically credible platform. At the same time, the investment case remains typical of an advanced-stage biotech: clinical and regulatory risk is still significant, commercialization is early, and ongoing funding needs remain material. Recent highlights include continued patient uptake for CASGEVY, positive Phase 1 data for CTX310, ongoing progress in zugo-cel, and a proposed $350 million convertible senior notes offering announced in March 2026 to strengthen financial flexibility and support the expanding pipeline. ([ir.crisprtx.com](https://ir.crisprtx.com/node/14691/pdf))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
